Vonoprazan
-
API Product :
Vonoprazan
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Antiulcerative
-
Originator :
Takeda Pharmaceutical
-
CAS No. :
881681-00-1
-
Trade Name. :
Takecab
-
Molecular Weight :
345.39 g·mol−1
-
Molecular Formula :
C17H16FN3O2S
Application
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
General Description
Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.